trending Market Intelligence /marketintelligence/en/news-insights/trending/m9u6se3LlxcWpQ7VnEuk-Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

FibroGen stocks up as drug shown to benefit lung patients

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

FibroGen stocks up as drug shown to benefit lung patients

FibroGen Inc. said it would advance the clinical development of pamrevlumab after the drug was shown to benefit idiopathic pulmonary fibrosis patients in phase 2 studies.

Pamrevlumab-treated patients had a significantly lower rate of decline in lung function as compared to the placebo-treated patients. The drug was also well-tolerated as a monotherapy as well as in combination with pirfenidone and nintedanib.

"We believe that the promising outcomes of these studies enable us to advance pamrevlumab into phase 3 clinical development," FibroGen CEO Thomas Neff said in a statement.

FibroGen shares were up 48.20% to $49.50 apiece at market close on Aug. 9.

Pamrevlumab is also being evaluated as a treatment of cancer.